<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/146209</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;146209</article-id><article-id pub-id-type="other" hwp:sub-type="slug">146209</article-id><article-id pub-id-type="other" hwp:sub-type="tag">146209</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Systems Biology" hwp:journal="biorxiv"><subject>Systems Biology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Network integration of multi-tumour omics data suggests novel targeting strategies</article-title></title-group><author-notes hwp:id="author-notes-1"><fn id="n1" hwp:id="fn-1" hwp:rev-id="xref-fn-1-1 xref-fn-1-2 xref-fn-1-3"><label>*</label><p hwp:id="p-1">These authors equally contributed to the paper</p></fn><corresp id="cor1" hwp:id="corresp-1" hwp:rev-id="xref-corresp-1-1"><label>§</label>Corresponding author: <email hwp:id="email-1">daniel.remondini@unibo.it</email></corresp></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Valle Ítalo Faria do"><surname>Valle</surname><given-names>Ítalo Faria do</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref><xref ref-type="author-notes" rid="n1" hwp:id="xref-fn-1-1" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Menichetti Giulia"><surname>Menichetti</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref><xref ref-type="author-notes" rid="n1" hwp:id="xref-fn-1-2" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Simonetti Giorgia"><surname>Simonetti</surname><given-names>Giorgia</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref><xref ref-type="author-notes" rid="n1" hwp:id="xref-fn-1-3" hwp:rel-id="fn-1">*</xref></contrib><contrib contrib-type="author" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Bruno Samantha"><surname>Bruno</surname><given-names>Samantha</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-2" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Zironi Isabella"><surname>Zironi</surname><given-names>Isabella</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-2" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Fernandes Durso Danielle"><surname>Fernandes Durso</surname><given-names>Danielle</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-3" hwp:rel-id="aff-4">4</xref><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Mombach José C M"><surname>Mombach</surname><given-names>José C M</given-names></name><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Martinelli Giovanni"><surname>Martinelli</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-4" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Castellani Gastone"><surname>Castellani</surname><given-names>Gastone</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-3" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-10"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3185-7456</contrib-id><name name-style="western" hwp:sortable="Remondini Daniel"><surname>Remondini</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-4" hwp:rel-id="aff-1">1</xref><xref ref-type="corresp" rid="cor1" hwp:id="xref-corresp-1-1" hwp:rel-id="corresp-1">§</xref><object-id pub-id-type="other" hwp:sub-type="orcid" xlink:href="http://orcid.org/0000-0003-3185-7456"/></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1 xref-aff-1-2 xref-aff-1-3 xref-aff-1-4"><label>1</label><institution hwp:id="institution-1">Department of Physics and Astronomy, University of Bologna</institution> – Bologna, <country>Italy</country></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1"><label>2</label><institution hwp:id="institution-2">CAPES Foundation, Ministry of Education of Brazil</institution> – Brasília (DF), <country>Brazil</country></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1"><label>3</label><institution hwp:id="institution-3">Department of Physics, Center for Complex Network Research, Northeastern University</institution>, Boston, Massachusetts 02115, <country>USA</country></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1 xref-aff-4-2 xref-aff-4-3 xref-aff-4-4"><label>4</label><institution hwp:id="institution-4">Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna</institution> – Bologna, <country>Italy</country></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1"><label>5</label><institution hwp:id="institution-5">National Counsel of Technological and Scientific Development (CNPq), Ministry of Science Technology and Innovation (MCTI)</institution>, Brasilia, <country>Brazil</country></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-6">Department of Physics, Universidade Federal de Santa Maria</institution>, Santa Maria, RS, <country>Brazi</country></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2017"><year>2017</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2017-06-05T07:53:46-07:00">
    <day>5</day><month>6</month><year>2017</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2017-06-05T07:53:46-07:00">
    <day>5</day><month>6</month><year>2017</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2017-06-05T08:01:12-07:00">
    <day>5</day><month>6</month><year>2017</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2017-06-05T08:01:12-07:00">
    <day>5</day><month>6</month><year>2017</year>
  </pub-date><elocation-id>146209</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2017-06-05"><day>05</day><month>6</month><year>2017</year></date>
<date date-type="rev-recd" hwp:start="2017-06-05"><day>05</day><month>6</month><year>2017</year></date>
<date date-type="accepted" hwp:start="2017-06-05"><day>05</day><month>6</month><year>2017</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2017, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2017</copyright-year><license hwp:id="license-1"><p hwp:id="p-2">The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.</p></license></permissions><self-uri xlink:href="146209.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/146209v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="146209.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/146209v1/146209v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/146209v1/146209v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><p hwp:id="p-3">We characterize different tumour types in the search for multi-tumour drug targets, in particular aiming for drug repurposing or novel drug combinations. Starting from 11 tumour types from The Cancer Genome Atlas, we obtain three clusters based on transcriptomic correlation profiles. A network-based analysis, integrating gene expression profiles and protein interactions of cancer-related genes, allowed us to define three cluster-specific signatures, with genes belonging to NF-ĸB signaling, chromosomal instability, ubiquitin-proteasome system, DNA metabolism, and apoptosis biological processes. These signatures have been characterized by different approaches based on mutational, pharmacological and clinical evidences, demonstrating the validity of our selection. Moreover, we defined new pharmacological strategies validated by <italic toggle="yes">in vitro</italic> experiments that showed inhibition of cell growth in two tumour cell lines, with significant synergistic effect. Our study thus provides a list of genes and pathways with the potential to be used, singularly or in combination, for the design of novel treatment strategies.</p></abstract><counts><page-count count="37"/></counts></article-meta></front><body><sec id="s1" hwp:id="sec-1"><title hwp:id="title-2">Introduction</title><p hwp:id="p-4">High-throughput molecular profiling has changed the approach to study cancer. For decades, anatomical localization and histological features have guided the identification of cancer subtypes, but the genomic profiling of tumour samples has revealed differences and similarities that go beyond the histopathological classification. The diversity in genomic alteration patterns often stratifies tumours from the same organ or tissue, while tumours in different tissues may present similar patterns<sup><xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>–<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref></sup>. For example, mutational profiling of transcription factors/regulators show tissue specificity, while histone modifiers can be mutated similarly across several cancer types<sup><xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref></sup>. Hoadley et. al.<sup><xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref></sup> suggests that lung squamous, head and neck, and a subset of bladder cancers form a unique cancer category typified by specific alterations, while copy number, protein expression, somatic mutations and activated pathways divide bladder cancer into different subtypes. The analysis of cancer transcriptomes revealed that the same tumour may originate from several cell types, and different biological processes may lead to malignant transformation<sup><xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-2" hwp:rel-id="ref-4">4</xref></sup>. Moreover, similar pathways may be activated in different cancers, like ovarian, endometrial and basal-like breast carcinomas<sup><xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>,<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref></sup>.</p><p hwp:id="p-5">Notwithstanding the enormous increase of knowledge on tumour processes, actually, a practical application of this knowledge to new treatment strategies has not advanced with the same pace. For example, common genetic alterations can predict similar responses to pharmacological therapies across multiple cancer cell lines<sup><xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>–<xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref></sup>, thus such common molecular and functional profiles could enable the repurposing of therapies from one cancer to another.</p><p hwp:id="p-6">The huge amount of heterogeneous types of data for a large number of tumours requires novel approaches capable to integrate such information into a unified framework: for this aim, we propose a study of gene networks based on expression profiling and mutational data, in combination with cancer-specific functional annotation. Starting from whole-genome transcriptional profiling extracted from The Cancer Genome Atlas (TCGA) data portal (<ext-link l:rel="related" l:ref-type="uri" l:ref="https://gdc-portal.nci.nih.gov/" ext-link-type="uri" xlink:href="https://gdc-portal.nci.nih.gov/" hwp:id="ext-link-1">https://gdc-portal.nci.nih.gov/</ext-link>), we selected a curated subset of cancer-related genes and pathways described in the Ontocancro database (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://ontocancro.inf.ufsm.br/" ext-link-type="uri" xlink:href="http://ontocancro.inf.ufsm.br/" hwp:id="ext-link-2">http://ontocancro.inf.ufsm.br/</ext-link>), and mapped these data onto the BioPlex protein-protein interaction network<sup><xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref></sup>. A structural analysis of the obtained networks, based on node centrality, allowed us to rank their relevance and to obtain specific signatures, that may provide multi-tumour drug targets, prognostic markers, and a molecular taxonomy for effective cancer categorization.</p><p hwp:id="p-7">The validation of our signatures through literature interrogation, clinical information and by <italic toggle="yes">in vitro</italic> testing, makes us confident that this study can help both clinical and research communities, providing novel targets for multi-drug approaches and for repurposing of existing drugs.</p></sec><sec id="s2" hwp:id="sec-2"><title hwp:id="title-3">Results</title><p hwp:id="p-8">We analyzed transcriptomic data of 2378 samples from 11 tumour types (<xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Table 1</xref>) considering 760 cancer-related genes with protein-protein interaction annotation (Bioplex-Ontocancro network, see Methods). The tumour datasets were clustered in three groups based on their gene-gene correlation matrices (see Methods) containing, respectively, 2, 6 and 3 cancer types: 1) Colon adenocarcinoma (COAD) and Rectum Adenocarcinoma (READ); 2) Lung Adenocarcinoma (LUAD), Lung Squamous Cell Carcinoma (LUSC), Glioblastoma Multiforme (GBM), Ovarian Serous Cystadenocarcinoma (OV), Breast Invasive Carcinoma (BRCA), and Uterine Corpus Endometrial Carcinoma (UCEC); and 3) Brain Lower Grade Glioma (LGG), Kidney Renal Clear Cell Carcinoma (KIRC), and Kidney Renal Papillary Cell Carcinoma (KIRP) (<xref ref-type="fig" rid="fig1" hwp:id="xref-fig-1-1" hwp:rel-id="F1">Figure 1</xref>). By superimposing the correlation matrices (specific to each cluster) onto the BioPlex-Ontocancro network (common to all tumours), we obtained three weighted networks with approximately 80% of the original nodes and 60% of the original edges (<xref ref-type="table" rid="tbl2" hwp:id="xref-table-wrap-2-1" hwp:rel-id="T2">Table 2</xref>, see Supplementary Figures 1-4).</p><fig id="fig1" position="float" orientation="portrait" fig-type="figure" hwp:id="F1" hwp:rev-id="xref-fig-1-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F1</object-id><object-id pub-id-type="publisher-id">fig1</object-id><label>Figure 1</label><caption hwp:id="caption-1"><title hwp:id="title-4">tumour clustering.</title><p hwp:id="p-9">For each tumour, we produced a matrix from the correlation (Pearson) of the expression profiles among 760 genes. The correlations values were adjusted by the CLR algorithm. Then, we clustered the resulting matrices by euclidean metrics.</p></caption><graphic xlink:href="146209_fig1" position="float" orientation="portrait" hwp:id="graphic-1"/></fig><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>Table 1</label><caption hwp:id="caption-2"><title hwp:id="title-5">The datasets.</title><p hwp:id="p-10">List of tumours and their respective number of gene expression arrays</p></caption><graphic xlink:href="146209_tbl1" position="float" orientation="portrait" hwp:id="graphic-2"/></table-wrap><table-wrap id="tbl2" orientation="portrait" position="float" hwp:id="T2" hwp:rev-id="xref-table-wrap-2-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/TBL2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tbl2</object-id><label>Table 2</label><caption hwp:id="caption-3"><title hwp:id="title-6">Network Properties.</title><p hwp:id="p-11">The table shows the main topological features of the cluster networks. Cluster 1: COAD and READ; Cluster 2: LUAD, LUSC, GBM, OV, BRCA, and UCEC; and Cluster 3: LGG, KIRC and KIRP.</p></caption><graphic xlink:href="146209_tbl2" position="float" orientation="portrait" hwp:id="graphic-3"/></table-wrap><p hwp:id="p-12">We hypothesized that the most central genes in each network should play a fundamental role in the tumours represented in the cluster. To find the most central genes we measured the Spectral Centrality (SC)<sup><xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref></sup>, related to the changes in network global diffusivity by node perturbation through a Laplacian formalism, and considered the nodes with SC above the 90<sup>th</sup> percentile (25, 27 and 24 genes for clusters 1,2, 3 respectively, <xref ref-type="table" rid="tbl3" hwp:id="xref-table-wrap-3-1" hwp:rel-id="T3">Table 3</xref>). We remark that the chosen signatures have only a small overlap with the most central nodes on the original “full” Bioplex-Ontocancro network not filtered by the cluster-specific correlation matrices (3/25, 13/27 and 4/24 common genes for clusters 1,2, 3, respectively) showing how the information on gene expression profile is highly specific for the considered tumour clusters. The top-ranking nodes also differ significantly from those obtained from other centrality measures such as degree and betweenness centrality (see Supplementary table 5). Moreover, even if some signature genes overlap between clusters, their links are different (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-1" hwp:rel-id="F2">Figures 2</xref>, <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-1" hwp:rel-id="F3">3</xref>, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-1" hwp:rel-id="F4">4</xref>, and Supplementary Figure 5) evidencing a specific interaction pattern.</p><fig id="fig2" position="float" orientation="portrait" fig-type="figure" hwp:id="F2" hwp:rev-id="xref-fig-2-1 xref-fig-2-2 xref-fig-2-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F2</object-id><object-id pub-id-type="publisher-id">fig2</object-id><label>Figure 2</label><caption hwp:id="caption-4"><p hwp:id="p-13">– Network composed by the first neighbors of the cluster 1 signature genes</p></caption><graphic xlink:href="146209_fig2" position="float" orientation="portrait" hwp:id="graphic-4"/></fig><fig id="fig3" position="float" orientation="portrait" fig-type="figure" hwp:id="F3" hwp:rev-id="xref-fig-3-1 xref-fig-3-2 xref-fig-3-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F3</object-id><object-id pub-id-type="publisher-id">fig3</object-id><label>Figure 3</label><caption hwp:id="caption-5"><p hwp:id="p-14">– Network composed by the first neighbors of the cluster 2 signature genes.</p></caption><graphic xlink:href="146209_fig3" position="float" orientation="portrait" hwp:id="graphic-5"/></fig><fig id="fig4" position="float" orientation="portrait" fig-type="figure" hwp:id="F4" hwp:rev-id="xref-fig-4-1 xref-fig-4-2 xref-fig-4-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F4</object-id><object-id pub-id-type="publisher-id">fig4</object-id><label>Figure 4</label><caption hwp:id="caption-6"><p hwp:id="p-15">– Network composed by the first first neighbors of the cluster 3 signature genes</p></caption><graphic xlink:href="146209_fig4" position="float" orientation="portrait" hwp:id="graphic-6"/></fig><table-wrap id="tbl3" orientation="portrait" position="float" hwp:id="T3" hwp:rev-id="xref-table-wrap-3-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/TBL3</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T3</object-id><object-id pub-id-type="publisher-id">tbl3</object-id><label>Table 3</label><caption hwp:id="caption-7"><title hwp:id="title-7">Gene Signatures.</title><p hwp:id="p-16">List of signature genes for the three tumour clusters.</p></caption><graphic xlink:href="146209_tbl3" position="float" orientation="portrait" hwp:id="graphic-7"/></table-wrap><p hwp:id="p-17">We observed that all signatures contain genes related to three biological categories: NF-ĸB signaling pathway, chromosomal instability and ubiquitin-proteasome system (<xref ref-type="table" rid="tbl4" hwp:id="xref-table-wrap-4-1" hwp:rel-id="T4">Table 4</xref>). The chromosomal instability category relates to genes involved in kinetochore formation, microtubule dynamics and chromosome segregation functions. All signatures have at least one substrate recognition component of E3 ubiquitin ligase complexes: <italic toggle="yes">BTRC</italic> in clusters 1 and 2; and <italic toggle="yes">FBXW11</italic> in cluster 3. Cluster 1 has genes involved in spindle checkpoint (<italic toggle="yes">BUB1, CDC20</italic>). The cluster 2 signature has many genes related to DNA repair (<italic toggle="yes">CETN2, FANCB, H2AFX, ERCC1, ERCC4, PARP1, XPA</italic>) and DNA replication (<italic toggle="yes">RPA2, MCM10</italic>). Moreover, it has three important genes in the signaling path that activates the <italic toggle="yes">STAT3</italic> transcription factor: <italic toggle="yes">SRC, NFKB1</italic> and <italic toggle="yes">IL6R</italic>. Indeed, the <italic toggle="yes">STAT3</italic> gene expression levels are significantly higher in cluster 2 (ANOVA p-value: 5.58 x 10<sup>−15</sup>) both in comparison with cluster 1 (T-Test p-value: 1.08 x 10<sup>−9</sup>) and cluster 3 (T-Test p-value: 1.14 x 10<sup>−8</sup>) patients (see Supplementary Figure 6). The cluster 3 signature contains genes involved in three different apoptotic mechanisms: induced by TNF-α (<italic toggle="yes">TNFRSF1A</italic> and <italic toggle="yes">BAG4</italic>), induced by Endoplasmatic Reticulum stress (<italic toggle="yes">CAPN1</italic> and <italic toggle="yes">CAPN2</italic>) and caspase-independent apoptosis (<italic toggle="yes">ENDOG</italic>).</p><table-wrap id="tbl4" orientation="portrait" position="float" hwp:id="T4" hwp:rev-id="xref-table-wrap-4-1 xref-table-wrap-4-2"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/TBL4</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T4</object-id><object-id pub-id-type="publisher-id">tbl4</object-id><label>Table 4</label><caption hwp:id="caption-8"><title hwp:id="title-8">Common biological categories present in the gene signatures.</title><p hwp:id="p-18">All cluster signatures have genes that can be grouped in the following categories: NF-ĸB signaling, chromosomal instability and ubiquitin-proteasome system.</p></caption><graphic xlink:href="146209_tbl4" position="float" orientation="portrait" hwp:id="graphic-8"/></table-wrap><p hwp:id="p-19">Then, we searched for possible relationships between the gene signatures and genes commonly mutated in the studied tumours. We observed that some signature genes also present somatic mutations (<italic toggle="yes">REL</italic> and <italic toggle="yes">RAD21</italic> in cluster 1, <italic toggle="yes">ERCC4</italic> and <italic toggle="yes">XPA</italic> in cluster 2, and <italic toggle="yes">AKT2</italic> in cluster 3) or that mutated genes are direct neighbors of the signature genes in the network (see <xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-2" hwp:rel-id="F2">Figures 2</xref>, <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-2" hwp:rel-id="F3">3</xref>, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-2" hwp:rel-id="F4">4</xref>). A permutation test over the signature labels (see Methods) reveals a significant proximity of signature genes to mutated genes for cluster 1 and cluster 2 (p-value=8.76 x 10<sup>−4</sup> and p-value=6.9 x 10<sup>−3</sup> respectively, Supplementary Figure 9). For the particular case of cluster 3, only one mutated gene is present in the network and it is successfully selected as a signature gene. These outcomes highlight the strict relationship between signature genes and key processes in tumour development (in analogy with the network-based approach of Novarino et. al.<sup><xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref></sup>).</p><p hwp:id="p-20">Since the signature genes are the most central nodes in each cluster, we hypothesized that they might be suitable drug targets. For this purpose we collected, from the DrugBank database, the drugs that target genes in the signatures (Supplementary Table 1) and we evaluated in the ClinicalTrials repository if these drugs are under ongoing clinical trials for cancer treatment. We observed that 11 genes from the cluster signatures are being tested: 4 and 3 genes, from cluster 1 and 2, respectively; 3 genes from both cluster 1 and 2; and 1 gene from both cluster 1 and 3 (<xref ref-type="table" rid="tbl5" hwp:id="xref-table-wrap-5-1" hwp:rel-id="T5">Table 5</xref>, Supplementary Table 2).</p><table-wrap id="tbl5" orientation="portrait" position="float" hwp:id="T5" hwp:rev-id="xref-table-wrap-5-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/TBL5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T5</object-id><object-id pub-id-type="publisher-id">tbl5</object-id><label>Table 5</label><caption hwp:id="caption-9"><p hwp:id="p-21">– List of genes from the signatures that are also being tested in ongoing clinical trials studies (according <ext-link l:rel="related" l:ref-type="uri" l:ref="https://ClincalTrials.gov" ext-link-type="uri" xlink:href="https://ClincalTrials.gov" hwp:id="ext-link-3">ClincalTrials.gov</ext-link>).</p></caption><graphic xlink:href="146209_tbl5" position="float" orientation="portrait" hwp:id="graphic-9"/></table-wrap><p hwp:id="p-22">We then asked whether the expression level of the signature genes could predict the patients survival in each cluster, independently of the tumour type. For cluster 1 and 3, survival information were available only for 17 and 32 patients, respectively, which resulted in non-significantly different survival curves, possibly due to the low power of the test (see Supplementary Figures 7 and 8). For cluster 2, we retrieved the clinical information for 448 patients: the survival curves showed that the gene signature significantly separated the patients in two groups according to good or bad survival outcome (Log-rank test p-value = 4.54 x 10<sup>−3</sup>, see Methods and <xref ref-type="fig" rid="fig5" hwp:id="xref-fig-5-1" hwp:rel-id="F5">Figure 5</xref>).</p><fig id="fig5" position="float" orientation="portrait" fig-type="figure" hwp:id="F5" hwp:rev-id="xref-fig-5-1"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG5</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F5</object-id><object-id pub-id-type="publisher-id">fig5</object-id><label>Figure 5</label><caption hwp:id="caption-10"><title hwp:id="title-9">Gene signature and survival outcome.</title><p hwp:id="p-23">The cluster 2 signature defined two groups of patients with significantly different Kaplan-Meier survival curves.</p></caption><graphic xlink:href="146209_fig5" position="float" orientation="portrait" hwp:id="graphic-10"/></fig><p hwp:id="p-24">We tried to translate our results into novel therapeutic strategies by applying, for a subset of tumours in cluster 2 (which contained the largest and most heterogeneous set of tumours), a set of drugs on targets taken from the signature and from related biological functions. We selected three drugs: Bortezomib, for targeting the proteasome and the NF-ĸB pathway; BI6727, for targeting the cluster 2 signature gene <italic toggle="yes">PLK1;</italic> and the PF-00477736 drug, to target the <italic toggle="yes">CHK1/2</italic> genes, which are not in the signature, but also plays a role in the DNA damage response. We tested these drugs, alone or in combination, on the glioblastoma cell line T98G and the breast adenocarcinoma model MCF-7. Both cell lines were highly sensitive to Bortezomib, with an IC50 of 200 nM for MCF-7 and 0.6 nM for T98G (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-1" hwp:rel-id="F6">Figure 6</xref>). BI6727 treatment reduced viability in a concentration-dependent manner in both models, with the glioblastoma model showing increased responsiveness (IC50 of 69.2 nM <italic toggle="yes">versus</italic> 1.8 μM for MCF-7, <xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-2" hwp:rel-id="F6">Figure 6</xref>). Moreover, both cell lines showed low response to <italic toggle="yes">CHK1/2</italic> inhibition, with IC50 of 26.9 μM for MCF-7 and 15.1 μM for T98G (<xref ref-type="fig" rid="fig6" hwp:id="xref-fig-6-3" hwp:rel-id="F6">Figure 6</xref>). We then asked whether these drugs might synergize in the selected models. Although the combinations of PF-00477736 with either BI6727 or Bortezomib did not show any additive or synergistic effect in both cell lines (data not shown), we observed a cooperation effect between inhibition of PLK1 and proteasome activity (<xref ref-type="fig" rid="fig7" hwp:id="xref-fig-7-1" hwp:rel-id="F7">Figure 7A-B</xref>). Indeed, we observed in the treatment with the drug combination that the cell viability was significantly lower compared with single agent treatments in MCF-7 cells (<xref ref-type="fig" rid="fig7" hwp:id="xref-fig-7-2" hwp:rel-id="F7">Figure 7A</xref>, p &lt; 0.05), showing a general additive effect (Supplementary Table 4). We observed low Combination Index values (&lt; 1) for both cell lines, indicating synergistic effect for all concentrations tested in the breast cancer model, and for selected concentrations in the glioblastoma model (<xref ref-type="fig" rid="fig7" hwp:id="xref-fig-7-3" hwp:rel-id="F7">Figure 7</xref>, Supplementary Tables 3 and 4).</p><fig id="fig6" position="float" orientation="portrait" fig-type="figure" hwp:id="F6" hwp:rev-id="xref-fig-6-1 xref-fig-6-2 xref-fig-6-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG6</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F6</object-id><object-id pub-id-type="publisher-id">fig6</object-id><label>Figure 6</label><caption hwp:id="caption-11"><title hwp:id="title-10"><italic toggle="yes">In vitro</italic> response of cancer cell lines from signature 2 to treatment with Bortezomib, BI6727 and PF-00477736 as single agents.</title><p hwp:id="p-25">MCF-7 and T98G cells were treated with increasing doses of Bortezomib (0.01 to 10 μΜ for MCF-7, 0.02 to 10 nM for T98G), BI6727 (0.04 to 10 μM for MCF-7, 0.004 to 10 μM for T98G), PF-00477736 (5.6 to 100 μM) and cell viability was measured 72h after drug administration by WST-1 assay (three independent experiments). Cell viability is represented as (mean ± SEM). IC50 values are reported in the boxes (GraphPad Prism 6).</p></caption><graphic xlink:href="146209_fig6" position="float" orientation="portrait" hwp:id="graphic-11"/></fig><fig id="fig7" position="float" orientation="portrait" fig-type="figure" hwp:id="F7" hwp:rev-id="xref-fig-7-1 xref-fig-7-2 xref-fig-7-3"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;146209v1/FIG7</object-id><object-id pub-id-type="other" hwp:sub-type="slug">F7</object-id><object-id pub-id-type="publisher-id">fig7</object-id><label>Figure 7</label><caption hwp:id="caption-12"><title hwp:id="title-11">Sensitivity of MCF-7 and T98G cells to combined inhibition of PLK1 and proteasome activity.</title><p hwp:id="p-26">MCF-7 and T98G cells were treated with increasing doses of Bortezomib (0.05 to 0.8 μM for MCF-7, 0.15 to 2.4 nM for T98G) and BI6727 (0.5 to 7.2 μM for MCF-7, 17 to 277 nM for T98G), alone or in combination and cell viability was measured 72h after drug administration by WST-1 assay (three independent experiments). Statistical significance was determined by Student’s t test (*, P &lt; 0.05; ***, P &lt; 0.001). Combination index (C.I.) was calculated by CompuSyn software. (A) MCF-7 cells: combinations with a C.I. lower than 0.5 are shown. (B) T98G cells: combinations showing synergistic effect are shown.</p></caption><graphic xlink:href="146209_fig7" position="float" orientation="portrait" hwp:id="graphic-12"/></fig></sec><sec id="s3" hwp:id="sec-3"><title hwp:id="title-12">Discussion and conclusion</title><p hwp:id="p-27">We studied the expression profiles of 11 tumours by considering a selected set of genes from the Ontocancro database and the BioPlex protein-protein interaction network. This knowledge-based selection reduced the dimensionality of the data to a highly curated list of cancer-related genes, involved in pathways that are hallmarks of cancer as cell cycle, inflammation, and apoptosis<sup><xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref></sup>. This approach also ensured that all studied genes had protein-protein interaction annotations, which are crucial to the understanding of how the signaling transduction propagates in the cell<sup><xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref></sup>. We clustered tumours by their gene-gene relationships defined by the Pearson’s correlation matrices, to evaluate the functional relationships between genes and their impact on transcriptome organization<sup><xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>,<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref></sup>. tumours from the same organ tended to group together, in agreement with previous studies showing that tissue-of-origin features provide the dominant signals in the identification of cancer subtypes<sup><xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">2</xref>,<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref></sup>. However, the clustering also grouped tumours originating from different tissues, according to similarities in genomic alterations, as in the case of BRCA, OV, LUSC, and UCEC, which share common characteristics as presence of <italic toggle="yes">TP53</italic> mutations and multiple recurrent chromosomal gains and losses<sup><xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-2" hwp:rel-id="ref-3">3</xref></sup>. In particular, BRCA and UCEC grouped into a well defined subcluster, which may reflect their better prognosis when compared to other 10 tumour types<sup><xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-3" hwp:rel-id="ref-2">2</xref></sup>.</p><p hwp:id="p-28">We integrated different types of biological information by a network approach, that allowed us to identify functional modules and to rank genes as network elements<sup><xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>,<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref></sup>. We created a network for each cluster (starting from a common template of protein interactions and superimposing cluster-specific correlation profiles) and obtained specific gene signatures based on node ranking by centrality measures. These signatures presented genes mainly involved in three biological processes: NF-ĸB signaling, chromosomal instability and the ubiquitin-proteasome system (<xref ref-type="table" rid="tbl4" hwp:id="xref-table-wrap-4-2" hwp:rel-id="T4">Table 4</xref>). The NF-ĸB signaling pathway regulates genes that participate in cell proliferation, innate and adaptive immune responses, inflammation, cell migration, and apoptosis regulation processes. The aberrant activity of NF-ĸB may act as survival factor for transformed cells which would otherwise become senescent or apoptotic<sup><xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref></sup>. The genes classified into the chromosomal instability category involve kinetochore formation, microtubule dynamics and chromosome segregation functions. The dysfunction in these genes may cause cell inability to faithfully segregate chromosomes, generating genomic alterations as DNA mutation, chromosomal translocation, and gene amplification. The mutant genotypes may confer beneficial phenotypic traits to cancer cells, such as sustained proliferative signaling and resistance to cell death<sup><xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-2" hwp:rel-id="ref-14">14</xref></sup>. Two genes classified into this category have already been related to clinical practice: the prognostic marker KIF2C<sup><xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>,<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref></sup>; and the <italic toggle="yes">BUB1</italic> gene, which expression correlates with poor clinical diagnosis<sup><xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>,<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref></sup>. The ubiquitin-proteasome system is the major degradation machinery that controls the abundance of critical regulatory proteins. Perturbation of the regulatory proteins turnover disturbs the intricate balance of signaling pathways and the cellular homeostasis, contributing to the multi-step process of malignant transformation<sup><xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref></sup>. Proteasome inhibitors have become valuable tools in the treatment of certain types of cancer, mainly because malignant cells show greater sensitivity to the cytotoxic effects of proteasome inhibition than non-cancer cells<sup><xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref></sup>.</p><p hwp:id="p-29">In addition to common features, cluster 2 signature has several genes related to DNA repair (<italic toggle="yes">CETN2, FANCB, H2AFX, ERCC1, ERCC4, PARP1, XPA</italic>) and DNA replication (<italic toggle="yes">RPA2, MCM10</italic>). Interestingly, the tumours in this cluster usually present high rates (50% to 90%) of samples with mutated <italic toggle="yes">TP53</italic>, which is an important sensor for the cell DNA damage response<sup><xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-4" hwp:rel-id="ref-2">2</xref>,<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-3" hwp:rel-id="ref-4">4</xref>,<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref></sup>. The cluster 2 signature also presents the genes <italic toggle="yes">SRC, NFKB</italic>, and <italic toggle="yes">IL6R</italic>, which participates in the activation of <italic toggle="yes">STAT3</italic>, a transcription factor that is necessary for cell transformation<sup><xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref></sup>. We observed that <italic toggle="yes">STAT3</italic> gene expression is higher in the tumours of cluster 2 when compared with the tumours of clusters 1 and 3 (Anova p-value: 5.58 x 10<sup>−15</sup>). The cluster 3 signature has genes involved in three apoptotic mechanisms, which are induced by TNF-α (<italic toggle="yes">TNFRSF1A</italic> and <italic toggle="yes">BAG4</italic>), or Endoplasmatic Reticulum stress (<italic toggle="yes">CAPN1</italic> and <italic toggle="yes">CAPN2</italic>) and caspase- independent apoptosis (<italic toggle="yes">ENDOG</italic>). As the regulation of cell death serves as a natural barrier to cancer development, these processes may reflect different strategies that these tumours use in response to various cellular stresses.</p><p hwp:id="p-30">Since the transcriptional disturbances observed in cancer can sometimes be explained by underlying somatic mutations<sup><xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>,<xref ref-type="bibr" rid="c31" hwp:id="xref-ref-31-1" hwp:rel-id="ref-31">31</xref></sup> we retrieved TCGA mutational data, and focused on cancer related mutations reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) database. Many signature genes resulted also somatically mutated, or first neighbours to mutated genes (<xref ref-type="fig" rid="fig2" hwp:id="xref-fig-2-3" hwp:rel-id="F2">Figures 2</xref>, <xref ref-type="fig" rid="fig3" hwp:id="xref-fig-3-3" hwp:rel-id="F3">3</xref>, <xref ref-type="fig" rid="fig4" hwp:id="xref-fig-4-3" hwp:rel-id="F4">4</xref>), showing their strict relationship and the functional relevance of the biologically processes they are involved in.</p><p hwp:id="p-31">In addition, several genes in the signatures or in their direct network neighborhood are already under clinical investigation in a variety of tumour conditions (as annotated in <ext-link l:rel="related" l:ref-type="uri" l:ref="https://Clinicaltrials.org" ext-link-type="uri" xlink:href="https://Clinicaltrials.org" hwp:id="ext-link-4">Clinicaltrials.org</ext-link> database). For example, the AKT pathway has been described as a potential drug intervention in clear cell renal carcinoma<sup><xref ref-type="bibr" rid="c32" hwp:id="xref-ref-32-1" hwp:rel-id="ref-32">32</xref></sup>: <italic toggle="yes">AKT2</italic> gene belongs to the signature of cluster 3 (comprising LGG, KIRC, and KIRP), it is somatically mutated in the tumours of cluster 3 and it has been annotated as drug-target according to the Drug Bank database.</p><p hwp:id="p-32">We also asked whether the gene signatures could predict survival outcomes in each cluster, thus independently on the tumour type. Our results show that in cluster 2 (the only one with enough available samples) the gene signature defined two groups of patients with significantly different Kaplan-Meier survival curves (log-rank test p-value: 4.54 x 10<sup>−3</sup>).</p><p hwp:id="p-33">Finally, we tested 3 existing drugs (targeting 2 genes belonging to cluster 2 signature, and 1 involved in a related biological process, but not directly belonging to the signature) on 2 tumour types of the cluster, T98G and MCF-7 models. PF-00477736 drug (a <italic toggle="yes">CHK1/2</italic> inhibitor, not in the signature)<sup><xref ref-type="bibr" rid="c33" hwp:id="xref-ref-33-1" hwp:rel-id="ref-33">33</xref></sup> had poor effect on both cell lines, but they resulted highly sensitive to BI6727 (an inhibitor of the signature gene PLK1<sup><xref ref-type="bibr" rid="c34" hwp:id="xref-ref-34-1" hwp:rel-id="ref-34">34</xref></sup>) and to Bortezomib (proteasome activity inhibitor<sup><xref ref-type="bibr" rid="c35" hwp:id="xref-ref-35-1" hwp:rel-id="ref-35">35</xref>,<xref ref-type="bibr" rid="c36" hwp:id="xref-ref-36-1" hwp:rel-id="ref-36">36</xref></sup>), with a significant synergic action at several dosages, suggesting a novel therapeutic strategy to be further explored in preclinical models of cluster 2 tumours.</p><p hwp:id="p-34">These observations indicate that our study succeeded in: 1) clustering tumours highlighting common functional mechanisms related to their transcriptional profile, and 2) selecting genes with a relevant functional role in the studied tumours, thus amenable of drug targeting. The combination of these results may thus provide the rationale for choosing novel drug targets and drug combinations, or for repurposing existing drugs towards tumours of the same cluster. As a possible future direction, once obtained an enlarged list of novel and repurposed drugs, the specific transcriptional and mutational profile of single patients, prioritized onto our signatures, might suggest specific combinations of drugs for a more targeted and personalized therapeutic approach.</p></sec><sec id="s4" hwp:id="sec-4"><title hwp:id="title-13">Methods</title><sec id="s4a" hwp:id="sec-5"><title hwp:id="title-14">Gene expression datasets</title><p hwp:id="p-35">The gene expression datasets used in this study were retrieved from The Cancer Genome Atlas (TCGA) Data Portal, and included Agilent expression arrays of 2378 samples from 11 tumour types, with a different number of samples each (from 16 to 595, see <xref ref-type="table" rid="tbl1" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Table 1</xref>). We selected for our analysis the genes from the BioPlex protein-protein interaction network<sup><xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-2" hwp:rel-id="ref-11">11</xref></sup> (n=10961) that were also present in the Ontocancro database (n=1104), resulting in a list of 760 cancer-associated genes related to specific biological functions (such as cell cycle control, DNA damage response, and inflammation).</p></sec><sec id="s4b" hwp:id="sec-6"><title hwp:id="title-15">tumour clustering</title><p hwp:id="p-36">For each tumour dataset, we calculated a correlation matrix containing pairwise Pearson r<sub>¡j</sub> coefficients between genes across all samples available for the tumour. In order to eliminate false correlations and indirect influences, the absolute correlation values (|r<sub>ij</sub>|) were adjusted with the Context Likelihood of Relatedness (CLR) algorithm<sup><xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-1" hwp:rel-id="ref-37">37</xref>,<xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-1" hwp:rel-id="ref-38">38</xref></sup> implemented in the R/Bioconductor package ‘minet’<sup><xref ref-type="bibr" rid="c39" hwp:id="xref-ref-39-1" hwp:rel-id="ref-39">39</xref></sup>. The matrices were clustered using hierarchical clustering analysis (with Ward linkage) based on the element-wise Euclidean distance between each pair of tumour matrices A and B, calculated as follows:
<disp-formula hwp:id="disp-formula-1"><alternatives hwp:id="alternatives-1"><graphic xlink:href="146209_ueqn1.gif" position="float" orientation="portrait" hwp:id="graphic-13"/></alternatives></disp-formula>
where <italic toggle="yes">a<sub>ij</sub></italic> is the correlation between the genes <italic toggle="yes">i</italic> and <italic toggle="yes">j</italic> in the tumour A and <italic toggle="yes">b<sub>ij</sub></italic> is the correlation between the genes <italic toggle="yes">i</italic> and <italic toggle="yes">j</italic> in the tumour B.</p></sec><sec id="s4c" hwp:id="sec-7"><title hwp:id="title-16">Multi-tumour gene signatures</title><p hwp:id="p-37">A network approach was applied to find gene signatures that characterized the clusters of tumours. First, we created a backbone network (BioPlex-Ontocancro) by selecting the genes present in the BioPlex protein-protein interaction network that were also annotated in the Ontocancro database. Then, for each cluster the gene-gene correlation coefficients r<sub>ij</sub> were computed, and their absolute values |r<sub>ij</sub>| were adjusted with the CLR algorithm, producing the z<sub>ij</sub> scores<sup><xref ref-type="bibr" rid="c37" hwp:id="xref-ref-37-2" hwp:rel-id="ref-37">37</xref>,<xref ref-type="bibr" rid="c38" hwp:id="xref-ref-38-2" hwp:rel-id="ref-38">38</xref></sup>. Each score matrix was superimposed to the BioPlex-Ontocancro network, producing three weighted networks (one for each cluster) in which genes were linked only if having correlated expression profiles (with weights given by positive z<sub>ij</sub> scores, specific to each cluster) and a physical interaction at protein level (given by Bioplex-Ontocancro network, common to all clusters). We remark that the three cluster-related networks result different because of different weight values, or missing links (due to negative z scores set to zero). The networks were analyzed and visualized by Networkx Python package, Matlab and Cytoscape<sup><xref ref-type="bibr" rid="c40" hwp:id="xref-ref-40-1" hwp:rel-id="ref-40">40</xref></sup>.</p><p hwp:id="p-38">For the networks of clusters 1 and 3, we selected the giant components (245 and 244 nodes, respectively), and for the cluster 2 we selected the two biggest components (149 and 118 nodes). After this selection, we retrieved a gene signature for each cluster composed by the most central genes (nodes), which were defined as those having the Spectral Centrality<sup><xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-2" hwp:rel-id="ref-12">12</xref></sup> topological measure SC above the 90<sup>th</sup> percentile. The SC calculates the effect of node removal on the network diffusivity based on the spectral properties of the Laplacian graph, and it has already been applied successfully to biological data such as the Immune System mediator network. Different results were obtained by considering Betweeness Centrality or weighted degree (Strength <italic toggle="yes">W</italic>) as centrality measures, as shown in Supplementary Table 5.</p></sec><sec id="s4d" hwp:id="sec-8"><title hwp:id="title-17">Validation of the multi-tumour gene signatures</title><p hwp:id="p-39">We evaluated the relevance of the genes in the signatures by several approaches.</p><p hwp:id="p-40">First, we verified the proximity with the somatic mutational data extracted from the TCGA data portal for the considered tumours. To avoid cancer unrelated mutations, we considered only mutations that were reported also in the Catalogue of Somatic Mutations in Cancer (COSMIC) database<sup><xref ref-type="bibr" rid="c41" hwp:id="xref-ref-41-1" hwp:rel-id="ref-41">41</xref></sup>. We checked whether the signature genes had been reported as somatic mutated or if they occurred in the neighborhood of mutated genes in the networks. To quantify the proximity of gene signatures to mutated genes we located the nearest mutation (in terms of shortest paths on the network) for each signature gene, resulting in a collection of minimum distance values for each cluster. The average minimum distance from the mutated genes <inline-formula hwp:id="inline-formula-1"><alternatives hwp:id="alternatives-2"><inline-graphic xlink:href="146209_inline1.gif" hwp:id="inline-graphic-1"/></alternatives></inline-formula>was then calculated for each cluster and tested with a permutation test. We performed 10<sup>6</sup> permutations of the signature labels and recalculated the average minimum distance of each new signature from the mutated genes. The p-values were calculated as
<disp-formula hwp:id="disp-formula-2"><alternatives hwp:id="alternatives-3"><graphic xlink:href="146209_ueqn2.gif" position="float" orientation="portrait" hwp:id="graphic-14"/></alternatives></disp-formula></p><p hwp:id="p-41">The results of the proximity analysis are reported in Supplementary Material Figure 9: the signatures of cluster 1 and cluster 2 are significantly closer to mutated genes than expected (p-values 9 x 10<sup>−4</sup> and 6.9 x 10<sup>−3</sup>, respectively). The permutation test for cluster 3 is not completely meaningful because there is only one mutated gene, that anyway results to be one of the signature genes.</p><p hwp:id="p-42">Secondly, we retrieved from the DrugBank<sup><xref ref-type="bibr" rid="c42" hwp:id="xref-ref-42-1" hwp:rel-id="ref-42">42</xref></sup> (<ext-link l:rel="related" l:ref-type="uri" l:ref="http://www.drugbank.ca/" ext-link-type="uri" xlink:href="http://www.drugbank.ca/" hwp:id="ext-link-5">http://www.drugbank.ca/</ext-link>) and Drug Gene Interaction (DGIdb)<sup><xref ref-type="bibr" rid="c43" hwp:id="xref-ref-43-1" hwp:rel-id="ref-43">43</xref></sup> databases which genes in the signatures were also mapped as drug targets. Third, we checked in the Aggregate Analysis of <ext-link l:rel="related" l:ref-type="uri" l:ref="https://ClinicalTrials.gov" ext-link-type="uri" xlink:href="https://ClinicalTrials.gov" hwp:id="ext-link-6">ClinicalTrials.gov</ext-link> (AACT) database (<ext-link l:rel="related" l:ref-type="uri" l:ref="https://www.ctti-clinicaltrials.org/aact-database" ext-link-type="uri" xlink:href="https://www.ctti-clinicaltrials.org/aact-database" hwp:id="ext-link-7">https://www.ctti-clinicaltrials.org/aact-database</ext-link>) for the existence of ongoing clinical trials evaluating the inhibition of genes in the signatures. Fourth, the prognostic potential of each gene signature was evaluated by considering the clinical data (days to death) available in the TCGA data portal. The patients having clinical information were clustered according to the expression levels of the gene signatures by using the k-means algorithm (Python package ‘scikit’), considering two patient groups: good versus bad survival outcome. Survivals curves were calculated for both groups: we applied the Kaplan-Meier method and evaluated their significance with the log-rank test (Python package “lifelines”). Fifth, we tested the effect of drugs inhibiting genes in our signatures or strictly related to them. The glioblastoma T98G and the breast adenocarcinoma MCF-7 cell lines were obtained from ATCC and DSMZ, respectively. Cells were cultured at a density of 10<sup>5</sup> cells/ml in RPMI medium plus 10% FBS (plus 5% Sodium orthovanadate for T98G) for 72h with increasing concentrations of the following drugs: Bortezomib, BI6727, PF-00477736 (Selleckchem), alone or in combination. One hour and 30 minutes before the end of treatment, WST-1 reagent was added to the cell medium and cell viability was measured according to manufacturer’s instruction (Roche). The dose-effect response and the IC50 of each drug were calculated using GraphPad Prism 6 (GraphPad Software). To determine synergy, combination indexes were obtained with the CompuSyn software (ComboSyn Inc.): combination index values &lt;1, =1, and &gt;1 indicate synergism, additive effect and antagonism, respectively.</p></sec></sec></body><back><sec id="s5" sec-type="supplementary-material" hwp:id="sec-9"><title hwp:id="title-18">Supplementary Information</title><p hwp:id="p-43">Supplementary Figure 1 – Bioplex-Ontocancro Network. Network built from the 760 genes found both in BioPlex protein-protein interaction network and Ontocancro database</p><p hwp:id="p-44">Supplementary Figure 2 – Overview of the cluster 1 network. Diamonds with red borders represent the genes in the cluster 1 signature and orange circles represent the mutated genes</p><p hwp:id="p-45">Supplementary Figure 3 – Overview of the cluster 2 network. Diamonds with red borders represent the genes in the cluster 2 signature and orange circles represent the mutated genes</p><p hwp:id="p-46">Supplementary Figure 4 – Overview of the cluster 3 network. Diamonds with red borders represent the genes in the cluster 3 signature and orange circles represent the mutated genes</p><p hwp:id="p-47">Supplementary Figure 5 – Network of signature genes common to cluster 1 and 2. Even though the signatures can present common genes, they have different set of interactors in each cluster network.</p><p hwp:id="p-48">Supplementary Figure 6 – Boxplot of STAT3 levels for clusters 1,2, 3. Cluster 2 patients presented higher STAT3 gene expression in comparison with cluster 1 (T-Test p-value: 1.08 x 10<sup>−9</sup>) and cluster 3 (T-Test p-value: 1.14 x 10<sup>−8</sup>).</p><p hwp:id="p-49">Supplementary Figure 7 – Kaplan-Meier curves for the two groups of cluster 1 patients defined by K-means clustering approach. The clustering was applied only to the genes in cluster 1 signature. Only 17 patients had the survival information in the TCGA data portal (logrank-test pvalue = 0.9118)</p><p hwp:id="p-50">Supplementary Figure 8 – Kaplan-Meier curves for the two groups of cluster 3 patients defined by K-means clustering approach. The clustering was applied considering only the genes in cluster 3 signature. Only 32 patients had the survival information in the TCGA data portal (logrank-test pvalue = 0.9056)</p><p hwp:id="p-51">Supplementary Figure 9 – Plot of the distribution of the 10<sup>6</sup> permutations for the 3 clusters (from left to right). The inboxes show the minimum average distances for the signatures (represented in the plots as red vertical lines), and the p-values with respect to the permutations.</p><p hwp:id="p-52">Supplementary Table 1 – List of drug-gene interactions for the genes in the signatures, extracted from the Drug Gene Interaction database (DGIdb).</p><p hwp:id="p-53">Supplementary Table 2 – List of ongoing clinical trials (according to <ext-link l:rel="related" l:ref-type="uri" l:ref="https://ClinicalTrials.gov" ext-link-type="uri" xlink:href="https://ClinicalTrials.gov" hwp:id="ext-link-8">ClinicalTrials.gov</ext-link>) that evaluate the inhibition of the genes in the signatures.</p><p hwp:id="p-54">Supplementary Table 3 – Combination Indexes for BI6727 and Bortezomib treatment at different concentrations in the T98G cell line.</p><p hwp:id="p-55">Supplementary Table 4 – Combination Indexes for BI6727 and Bortezomib treatment at different concentrations in the MCF-7 cell line.</p><p hwp:id="p-56">Supplementary Table 5 – Spearman’s rank correlation values for the centrality measures (Spectral Centrality SC, Betweenness Centrality BC, strength W) on the nodes for the 3 clusters. The results refer to the whole node list (“All”) or only to the signatures, obtained as the top 10% of the ranked measures (“90th”). We remark the drop in correlation when considering only the gene signatures obtained by the different centrality measures.</p></sec><sec id="s6" hwp:id="sec-10"><title hwp:id="title-19">List of Abbreviations</title><def-list hwp:id="def-list-1"><def-item hwp:id="def-item-1"><term hwp:id="term-1">TCGA</term><def hwp:id="def-1"><p hwp:id="p-57">The Cancer Genome Atlas</p></def></def-item><def-item hwp:id="def-item-2"><term hwp:id="term-2">SC</term><def hwp:id="def-2"><p hwp:id="p-58">Spectral Centrality</p></def></def-item><def-item hwp:id="def-item-3"><term hwp:id="term-3">COAD</term><def hwp:id="def-3"><p hwp:id="p-59">Colon Adenocarcinoma</p></def></def-item><def-item hwp:id="def-item-4"><term hwp:id="term-4">READ</term><def hwp:id="def-4"><p hwp:id="p-60">Rectum Adenocarcinoma</p></def></def-item><def-item hwp:id="def-item-5"><term hwp:id="term-5">LUAD</term><def hwp:id="def-5"><p hwp:id="p-61">Lung Adenocarcinoma</p></def></def-item><def-item hwp:id="def-item-6"><term hwp:id="term-6">LUSC</term><def hwp:id="def-6"><p hwp:id="p-62">Lung Squamous Cell Carcinoma</p></def></def-item><def-item hwp:id="def-item-7"><term hwp:id="term-7">GBM</term><def hwp:id="def-7"><p hwp:id="p-63">Glioblastoma Multiforme</p></def></def-item><def-item hwp:id="def-item-8"><term hwp:id="term-8">OV</term><def hwp:id="def-8"><p hwp:id="p-64">Ovarian Serous Cystadenocarcinoma</p></def></def-item><def-item hwp:id="def-item-9"><term hwp:id="term-9">BRCA</term><def hwp:id="def-9"><p hwp:id="p-65">Breast Invasive Carcinoma</p></def></def-item><def-item hwp:id="def-item-10"><term hwp:id="term-10">UCEC</term><def hwp:id="def-10"><p hwp:id="p-66">Uterine Corpus Endometrial Carcinoma</p></def></def-item><def-item hwp:id="def-item-11"><term hwp:id="term-11">LGG</term><def hwp:id="def-11"><p hwp:id="p-67">Brain Lower Grade Glioma</p></def></def-item><def-item hwp:id="def-item-12"><term hwp:id="term-12">KIRC</term><def hwp:id="def-12"><p hwp:id="p-68">Kidney Renal Clear Cell Carcinoma</p></def></def-item><def-item hwp:id="def-item-13"><term hwp:id="term-13">KIRP</term><def hwp:id="def-13"><p hwp:id="p-69">Kidney Renal Papillary Cell Carcinoma</p></def></def-item></def-list></sec><sec id="s7" hwp:id="sec-11"><title hwp:id="title-20">Competing interests</title><p hwp:id="p-70">The others authors declare that they have no competing interests.</p></sec><sec id="s8" hwp:id="sec-12"><title hwp:id="title-21">Authors’ Contributions</title><p hwp:id="p-71">IFV, GM and GS contributed equally to the paper. GS, SB, IZ and DFD performed the experiments and interpreted the results. IFV, GM and JCM collected and analyzed the data. GM, GC and DR designed the research, interpreted the results, wrote the paper.</p></sec><ack hwp:id="ack-1"><title hwp:id="title-22">Acknowledgements</title><p hwp:id="p-72">We thank the Science Without Borders project of CAPES foundation (Ministry of Education of Brazil – Brasilia -DF, Brazil) for the doctoral scholarship (grant number: 10186-13-1) for IFV. This study was supported by the Interomics CNR Flagship Initiative; Mimomics EU FP7 Project n. 305280; NGS PTL EU FP7 Project n. 306242; the CNPq Project n. 402547/2012-8; the Associazione Italiana per la Ricerca sul Cancro AIRC (Investigator Grant to GM, n. 19226); the Programma di ricerca Regione- Universita 2010-2012 (L. Bolondi); and the Innovative Medicines Initiative (IMI) 2 project “HARMONY”, n 116026.</p></ack><ref-list hwp:id="ref-list-1"><title hwp:id="title-23">References</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Chang K."><surname>Chang</surname>, <given-names>K.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-2">The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source hwp:id="source-1">Nat. Genet</source>. <volume>45</volume>, <fpage>1113</fpage>–<lpage>1120</lpage> (<year>2013</year>).</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2 xref-ref-2-3 xref-ref-2-4"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Hoadley K. a."><surname>Hoadley</surname>, <given-names>K. a.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-3">Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across tissues of origin</article-title>. <source hwp:id="source-2">Cell</source> <volume>158</volume>, <fpage>929</fpage>–<lpage>944</lpage> (<year>2013</year>).</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1 xref-ref-3-2"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Ciriello G."><surname>Ciriello</surname>, <given-names>G.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-4">Emerging landscape of oncogenic signatures across human cancers</article-title>. <source hwp:id="source-3">Nat Genet</source>. <volume>45</volume>, <fpage>1127</fpage>–<lpage>1133</lpage> (<year>2013</year>).</citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1 xref-ref-4-2 xref-ref-4-3"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Kandoth C."><surname>Kandoth</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-5">Mutational landscape and significance across 12 major cancer types</article-title>. <source hwp:id="source-4">Nature</source> <volume>502</volume>, <fpage>333</fpage>–<lpage>9</lpage> (<year>2013</year>).</citation></ref><ref id="c5" hwp:id="ref-5"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Verhaak R. G. W."><surname>Verhaak</surname>, <given-names>R. G. W.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-6">Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1</article-title>. <source hwp:id="source-5">Cancer Cell</source> <volume>17</volume>, <fpage>98</fpage>–<lpage>110</lpage> (<year>2010</year>).</citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Koboldt D. C."><surname>Koboldt</surname>, <given-names>D. C.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-7">Comprehensive molecular portraits of human breast tumours</article-title>. <source hwp:id="source-6">Nature</source> <volume>490</volume>, <fpage>61</fpage>–<lpage>70</lpage> (<year>2012</year>).</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Network C. G. A. R."><surname>Network</surname>, <given-names>C. G. A. R.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-8">Integrated genomic characterization of endometrial carcinoma</article-title>. <source hwp:id="source-7">Nature</source> <volume>497</volume>, <fpage>67</fpage>–<lpage>73</lpage> (<year>2013</year>).</citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><string-name name-style="western" hwp:sortable="Barretina J."><surname>Barretina</surname>, <given-names>J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-9">The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source hwp:id="source-8">Nature</source> <volume>483</volume>, <fpage>603</fpage>–<lpage>7</lpage> (<year>2012</year>).</citation></ref><ref id="c9" hwp:id="ref-9"><label>9.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.9" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-9"><string-name name-style="western" hwp:sortable="Garnett M. J."><surname>Garnett</surname>, <given-names>M. J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-10">Systematic identification of genomic markers of drug sensitivity in cancer cells</article-title>. <source hwp:id="source-9">Nature</source> <volume>483</volume>, <fpage>570</fpage>–<lpage>5</lpage> (<year>2012</year>).</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.10" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-10"><string-name name-style="western" hwp:sortable="Heiser L. M."><surname>Heiser</surname>, <given-names>L. M.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-11">Subtype and pathway specific responses to anticancer compounds in breast cancer</article-title>. <source hwp:id="source-10">Proc. Natl. Acad. Sci. U. S. A</source>. <volume>109</volume>, <fpage>2724</fpage>–<lpage>9</lpage> (<year>2012</year>).</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1 xref-ref-11-2"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Huttlin E. L."><surname>Huttlin</surname>, <given-names>E. L.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-12">The BioPlex Network: A Systematic Exploration of the Human Interactome</article-title>. <source hwp:id="source-11">Cell</source> <volume>162</volume>, <fpage>425</fpage>–<lpage>440</lpage> (<year>2015</year>).</citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1 xref-ref-12-2"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Pauls S. D."><surname>Pauls</surname>, <given-names>S. D.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Remondini D."><surname>Remondini</surname>, <given-names>D.</given-names></string-name> <article-title hwp:id="article-title-13">Measures of centrality based on the spectrum of the Laplacian</article-title>. <source hwp:id="source-12">Phys. Rev. E – Stat. Nonlinear, Soft Matter Phys</source>. <volume>85</volume>, <fpage>066127</fpage> (<year>2012</year>).</citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Novarino G."><surname>Novarino</surname>, <given-names>G.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-14">Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders</article-title>. <source hwp:id="source-13">Science</source> <volume>343</volume>, <fpage>506</fpage>–<lpage>511</lpage> (<year>2014</year>)</citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1 xref-ref-14-2"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Hanahan D."><surname>Hanahan</surname>, <given-names>D.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Weinberg R. A."><surname>Weinberg</surname>, <given-names>R. A.</given-names></string-name> <article-title hwp:id="article-title-15">Hallmarks of cancer: the next generation</article-title>. <source hwp:id="source-14">Cell</source> <volume>144</volume>, <fpage>646</fpage>–<lpage>74</lpage> (<year>2011</year>).</citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Vinayagam A"><surname>Vinayagam</surname>, <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-16">A Directed Protein Interaction Network for Investigating Intracellular Signal Transduction</article-title>. <source hwp:id="source-15">Sci. Signal</source>. <volume>4</volume>, <fpage>rs8</fpage>–<lpage>rs8</lpage> (<year>2011</year>).</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Lee H. K."><surname>Lee</surname>, <given-names>H. K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hsu A. K."><surname>Hsu</surname>, <given-names>A. K.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sajdak J."><surname>Sajdak</surname>, <given-names>J.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Qin J."><surname>Qin</surname>, <given-names>J.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Pavlidis P."><surname>Pavlidis</surname>, <given-names>P.</given-names></string-name> <article-title hwp:id="article-title-17">Coexpression analysis of human genes across many microarray data sets</article-title>. <source hwp:id="source-16">Genome Res</source>. <volume>14</volume>, <fpage>1085</fpage>–<lpage>94</lpage> (<year>2004</year>).</citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Eisen M. B."><surname>Eisen</surname>, <given-names>M. B.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spellman P. T."><surname>Spellman</surname>, <given-names>P. T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brown P. O."><surname>Brown</surname>, <given-names>P. O.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Botstein D."><surname>Botstein</surname>, <given-names>D.</given-names></string-name> <article-title hwp:id="article-title-18">Cluster analysis and display of genome-wide expression patterns</article-title>. <source hwp:id="source-17">Proc. Natl. Acad. Sci. U. S. A</source>. <volume>95</volume>, <fpage>14863</fpage>–<lpage>8</lpage> (<year>1998</year>).</citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Martínez E."><surname>Martínez</surname>, <given-names>E.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-19">Comparison of gene expression patterns across 12 tumour types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects</article-title>. <source hwp:id="source-18">Oncogene</source> <volume>34</volume>, <fpage>2732</fpage>–<lpage>2740</lpage> (<year>2015</year>).</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Ideker T."><surname>Ideker</surname>, <given-names>T.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Sharan R."><surname>Sharan</surname>, <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-20">Protein networks in diseases</article-title>. <source hwp:id="source-19">Genome Res</source>. <volume>18</volume>, <fpage>644</fpage>–<lpage>652</lpage> (<year>2008</year>).</citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Castellani G. C."><surname>Castellani</surname>, <given-names>G. C.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-21">Systems medicine of inflammaging</article-title>. <source hwp:id="source-20">Brief. Bioinform</source>. <fpage>1</fpage>–<lpage>14</lpage> (<year>2015</year>). doi: <pub-id pub-id-type="doi">10.1093/bib/bbv062</pub-id></citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Hoesel B."><surname>Hoesel</surname>, <given-names>B.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Schmid J. A."><surname>Schmid</surname>, <given-names>J. A.</given-names></string-name> <article-title hwp:id="article-title-22">The complexity of NF-ĸB signaling in inflammation and cancer</article-title>. <source hwp:id="source-21">Mol. Cancer</source> <volume>12</volume>, <fpage>86</fpage> (<year>2013</year>).</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Bie L."><surname>Bie</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhao G."><surname>Zhao</surname>, <given-names>G.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wang Y"><surname>Wang</surname>, <given-names>Y</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Zhang B."><surname>Zhang</surname>, <given-names>B.</given-names></string-name> <article-title hwp:id="article-title-23">Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas</article-title>. <source hwp:id="source-22">Clin. Neurol. Neurosurg</source>. <volume>114</volume>, <fpage>356</fpage>–<lpage>60</lpage> (<year>2012</year>).</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Sanhaji M."><surname>Sanhaji</surname>, <given-names>M.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Friel C. T."><surname>Friel</surname>, <given-names>C. T.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Wordeman L."><surname>Wordeman</surname>, <given-names>L.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Louwen F."><surname>Louwen</surname>, <given-names>F.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Yuan J."><surname>Yuan</surname>, <given-names>J.</given-names></string-name> <article-title hwp:id="article-title-24">Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target</article-title>. <source hwp:id="source-23">Oncotarget</source> <volume>2</volume>, <fpage>935</fpage>–<lpage>947</lpage> (<year>2011</year>).</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Bie L."><surname>Bie</surname>, <given-names>L.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-25">The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression</article-title>. <source hwp:id="source-24">PLoS One</source> <volume>6</volume>, <fpage>e25631</fpage> (<year>2011</year>).</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Finetti P."><surname>Finetti</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-26">Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis</article-title>. <source hwp:id="source-25">Cancer Res</source>. <volume>68</volume>, <fpage>767</fpage>–<lpage>76</lpage> (<year>2008</year>).</citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Sahasrabuddhe A. A."><surname>Sahasrabuddhe</surname>, <given-names>A. A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Elinitoba-Johnson K. S. J."><surname>Elinitoba-Johnson</surname>, <given-names>K. S. J.</given-names></string-name> <article-title hwp:id="article-title-27">Role of the ubiquitin proteasome system in hematologic malignancies</article-title>. <source hwp:id="source-26">Immunol. Rev</source>. <volume>263</volume>, <fpage>224</fpage>–<lpage>239</lpage> (<year>2015</year>).</citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Saez I."><surname>Saez</surname>, <given-names>I.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Vilchez D."><surname>Vilchez</surname>, <given-names>D.</given-names></string-name> <article-title hwp:id="article-title-28">The Mechanistic Links Between Proteasome Activity, Aging and Age-related Diseases</article-title>. <source hwp:id="source-27">Curr. Genomics</source> <volume>15</volume>, <fpage>38</fpage>–<lpage>51</lpage> (<year>2014</year>).</citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Collisson E. a."><surname>Collisson</surname>, <given-names>E. a.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-29">Comprehensive molecular profiling of lung adenocarcinoma</article-title>. <source hwp:id="source-28">Nature</source> <volume>511</volume>, <fpage>543</fpage>–<lpage>50</lpage> (<year>2014</year>).</citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Iliopoulos D."><surname>Iliopoulos</surname>, <given-names>D.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hirsch H. A."><surname>Hirsch</surname>, <given-names>H. A.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Struhl K."><surname>Struhl</surname>, <given-names>K.</given-names></string-name> <article-title hwp:id="article-title-30">An Epigenetic NF-ĸB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation</article-title>. <source hwp:id="source-29">Cell</source> <volume>139</volume>, <fpage>693</fpage>–<lpage>706</lpage> (<year>2009</year>).</citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Shlien A."><surname>Shlien</surname>, <given-names>A.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-31">Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer</article-title>. <source hwp:id="source-30">Cell Rep</source>. <volume>16</volume>, <fpage>2032</fpage>–<lpage>2046</lpage> (<year>2016</year>).</citation></ref><ref id="c31" hwp:id="ref-31" hwp:rev-id="xref-ref-31-1"><label>31.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.31" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-31"><string-name name-style="western" hwp:sortable="Sørlie T."><surname>Sørlie</surname>, <given-names>T.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-32">Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications</article-title>. <source hwp:id="source-31">Proc. Natl. Acad. Sci. U. S. A.</source> <volume>98</volume>, <fpage>10869</fpage>–<lpage>74</lpage> (<year>2001</year>).</citation></ref><ref id="c32" hwp:id="ref-32" hwp:rev-id="xref-ref-32-1"><label>32.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.32" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-32"><string-name name-style="western" hwp:sortable="Creighton C. J."><surname>Creighton</surname>, <given-names>C. J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-33">Comprehensive molecular characterization of clear cell renal cell carcinoma</article-title>. <source hwp:id="source-32">Nature</source> <volume>499</volume>, <fpage>43</fpage>–<lpage>9</lpage> (<year>2013</year>).</citation></ref><ref id="c33" hwp:id="ref-33" hwp:rev-id="xref-ref-33-1"><label>33.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.33" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-33"><string-name name-style="western" hwp:sortable="Lee C."><surname>Lee</surname>, <given-names>C.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-34">Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumour cells in part through loss of SOX2 and delays tumour progression in mice</article-title>. <source hwp:id="source-33">Stem Cells</source> <volume>30</volume>, <fpage>1064</fpage>–<lpage>75</lpage> (<year>2012</year>).</citation></ref><ref id="c34" hwp:id="ref-34" hwp:rev-id="xref-ref-34-1"><label>34.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.34" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-34"><string-name name-style="western" hwp:sortable="Bhola N. E."><surname>Bhola</surname>, <given-names>N. E.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-35">Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer</article-title>. <source hwp:id="source-34">Cancer Res</source>. <volume>75</volume>, <fpage>405</fpage>–<lpage>14</lpage> (<year>2015</year>).</citation></ref><ref id="c35" hwp:id="ref-35" hwp:rev-id="xref-ref-35-1"><label>35.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.35" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-35"><string-name name-style="western" hwp:sortable="Thaler S."><surname>Thaler</surname>, <given-names>S.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-36">The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer</article-title>. <source hwp:id="source-35">Int. J. Cancer</source> <volume>137</volume>, <fpage>686</fpage>–<lpage>97</lpage> (<year>2015</year>).</citation></ref><ref id="c36" hwp:id="ref-36" hwp:rev-id="xref-ref-36-1"><label>36.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.36" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-36"><string-name name-style="western" hwp:sortable="Yin D."><surname>Yin</surname>, <given-names>D.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-37">Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)</article-title>. <source hwp:id="source-36">Oncogene</source> <volume>24</volume>, <fpage>344</fpage>–<lpage>54</lpage> (<year>2005</year>).</citation></ref><ref id="c37" hwp:id="ref-37" hwp:rev-id="xref-ref-37-1 xref-ref-37-2"><label>37.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.37" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-37"><string-name name-style="western" hwp:sortable="Saccenti E"><surname>Saccenti</surname>, <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-38">Entropy-Based Network Representation of the Individual Metabolic Phenotype</article-title>. <source hwp:id="source-37">J. Proteome Res</source>. <volume>15</volume> (<issue>9</issue>), <fpage>3298</fpage>–<lpage>307</lpage> (<year>2016</year>).</citation></ref><ref id="c38" hwp:id="ref-38" hwp:rev-id="xref-ref-38-1 xref-ref-38-2"><label>38.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.38" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-38"><string-name name-style="western" hwp:sortable="Faith J. J."><surname>Faith</surname>, <given-names>J. J.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-39">Large-scale mapping and validation of <italic toggle="yes">Escherichia coli</italic> transcriptional regulation from a compendium of expression profiles</article-title>. <source hwp:id="source-38">PLoS Biol</source>. <volume>5</volume>, <fpage>0054</fpage>–<lpage>0066</lpage> (<year>2007</year>).</citation></ref><ref id="c39" hwp:id="ref-39" hwp:rev-id="xref-ref-39-1"><label>39.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.39" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-39"><string-name name-style="western" hwp:sortable="Meyer P. E."><surname>Meyer</surname>, <given-names>P. E.</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lafitte F."><surname>Lafitte</surname>, <given-names>F.</given-names></string-name> &amp; <string-name name-style="western" hwp:sortable="Bontempi G."><surname>Bontempi</surname>, <given-names>G.</given-names></string-name> <article-title hwp:id="article-title-40">minet: A R/Bioconductor package for inferring large transcriptional networks using mutual information</article-title>. <source hwp:id="source-39">BMC Bioinformatics</source> <volume>9</volume>, <fpage>461</fpage> (<year>2008</year>).</citation></ref><ref id="c40" hwp:id="ref-40" hwp:rev-id="xref-ref-40-1"><label>40.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.40" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-40"><string-name name-style="western" hwp:sortable="Shannon P."><surname>Shannon</surname>, <given-names>P.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-41">Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title>. <source hwp:id="source-40">Genome Res</source>. <volume>13</volume>, <fpage>2498</fpage>–<lpage>504</lpage> (<year>2003</year>).</citation></ref><ref id="c41" hwp:id="ref-41" hwp:rev-id="xref-ref-41-1"><label>41.</label><citation publication-type="other" citation-type="journal" ref:id="146209v1.41" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-41"><string-name name-style="western" hwp:sortable="Forbes S. A."><surname>Forbes</surname>, <given-names>S. A.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-42">The Catalogue of Somatic Mutations in Cancer (COSMIC)</article-title>. <source hwp:id="source-41">Curr. Protoc. Hum. Genet</source>. Chapter 10, Unit 10.11 (<year>2008</year>).</citation></ref><ref id="c42" hwp:id="ref-42" hwp:rev-id="xref-ref-42-1"><label>42.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.42" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-42"><string-name name-style="western" hwp:sortable="Wishart D. S."><surname>Wishart</surname>, <given-names>D. S.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-43">DrugBank: a comprehensive resource for in silico drug discovery and exploration</article-title>. <source hwp:id="source-42">Nucleic Acids Res</source>. <volume>34</volume>, <fpage>D668</fpage>–<lpage>72</lpage> (<year>2006</year>).</citation></ref><ref id="c43" hwp:id="ref-43" hwp:rev-id="xref-ref-43-1"><label>43.</label><citation publication-type="journal" citation-type="journal" ref:id="146209v1.43" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-43"><string-name name-style="western" hwp:sortable="Wagner A. H."><surname>Wagner</surname>, <given-names>A. H.</given-names></string-name> <etal>et al.</etal> <article-title hwp:id="article-title-44">DGIdb 2.0: mining clinically relevant drug-gene interactions</article-title>. <source hwp:id="source-43">Nucleic Acids Res</source>. <volume>44</volume>, <fpage>D1036</fpage>–<lpage>44</lpage> (<year>2016</year>).</citation></ref></ref-list></back></article>
